

Amendments to the Specification:

Please insert the paper copy of the Sequence Listing filed herewith following the Drawings.

Please insert the following paragraph after the title:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a National Stage of International Application No. PCT/US03/07323, filed March 7, 2003, which claims the benefit of priority from U.S. Provisional Application Serial No. 60/362,655, filed March 8, 2002.

Replace the paragraph beginning at page 5, line 23 with the following rewritten paragraph:

Fig. 8 is a representation of the nucleic acid sequence of MoMLV envelope protein (SEQ ID NO:4).

Replace the paragraph beginning at page 6, line 31 with the following rewritten paragraph:

Heterologous short peptide ligands suitable for use in the invention can also be identified using methods known in the art. Such methods include screening phage display in which a library of phage bearing a random selection of small peptides is selected for binding to the extracellular domain of a cell surface protein (i.e., a cell surface protein expressed on a host target cell). Nucleic acid sequences coding for such peptides are then cloned into wild-type envelope protein to produce chimeric envelope proteins. In another method using phage library, targeting to various organs can be achieved by injecting a phage display library into animals and identifying the peptides localized in each organ. This method has been successfully used to identify short peptides targeted to, e.g., kidney cells (CLPVASC, SEQ ID NO:3; ~~CLPVASC, SEQ ID NO:4~~; and CGAREMC, SEQ ID NO:5) and to brain cells (CLSSRLDAC, SEQ ID

NO:6; WRCVLREGPAGGCAWFNRHRL; SEQ ID NO:7) (Pasqualini et al., 1996, Nature 380:364-366). Similarly, recombinant peptide libraries can also be screened for peptides that specifically bind to a protein that is expressed on a target host cell (Pasqualini *supra*; Wrighton et al., 1996, Science 273:458-464; Cwirla et al., 1997, Science 276:1696-1699; Arap et al., 1998, Science 279:377-380).

Replace the Table 1 beginning at page 17 with the following rewritten Table 1:

Table 1. Description of RGD viruses.

| ENV # | Position of Ligand Insertion (A.A. Location) | | # of Inserts | Deletion of Nucleotides in Env. |
|---|---|-----|--------------|------------------------------------|
| RGD₁₃[CAAA-GRGDSP-TRC] (SEQ ID NO:8) | | | | |
| 1 | 1 | 1X | | |
| 2 | | 1 | 2X | |
| 3 | | 1 | 4X | |
| 4 | 38 | 1X | | |
| 5 | 38 | 3X | | |
| 6 | | 38 | 1X | 5990-6082 |
| 7 | 68 | 1X | | |
| 8 | 68 | 2X | | |
| 9 | | 68 | 1X | 6082-6191 |
| 10 | 120 | 1X | | |
| 11 | | 120 | 2X | 6238-6281 |
| 12 | 120 | 3X | | |
| 13 | 185 | 1X | | |
| 14 | 230 | 1X | | |
| 15 | 230 | 2X | | |
| 16 | 235 | 1X | | |
| 17 | 235 | 4X | | |
| 18 | 310 | 1X | | |
| 19 | 310 | 2X | | |
| 20 | 321 | 1X | | |
| 21 | 321 | 2X | | |
| 22 | 382 | 1X | | |
| 23 | 382 | 2X | | |
| 24 | 382 | 3X | | |
| 25 | 388 | 1X | | |
| 26 | 388 | | 2X | |
| RGD₂₁[CAAA-QGATFALRGDNPQG-TRC] (SEQ ID NO:11) | | | | |
| 1 | 1 | 1X | | |
| 2 | 38 | 1X | | |
| 3 | 38 | 1X | | 5990-6082 |
| 4 | 68 | 1X | | |
| 5 | 68 | 1X | | 6082-6191 |

Applicant : Michael R. Green et al.
 Serial No. : Not yet assigned
 Filed : Herewith
 Page : 4 of 6

Attorney's Docket No.: 07917-166US1 / UMMC 02-28

| | | | |
|----|-------|-------|-----------|
| 6 | 120 | 1X | |
| R | 120 | 1X | 6238-6281 |
| 8 | 185 | 1X | |
| 9 | 230 | 1X | |
| 10 | 235 | 1X | |
| 11 | 310 | 1X | |
| 12 | 321 | 1X | |
| 13 | 382 | 1X | |
| 14 | 388 | 1X | |
| 15 | 1,68 | 1X,1X | |
| 16 | 1,230 | 1X,1X | |

RGE₂₁ [CAAA- QGATFALRGENPQG-TRC] (SEQ ID NO:25)

| | | | |
|---|-----|----|-----------|
| 1 | 1 | 1X | |
| 2 | 38 | 1X | 5990-6082 |
| 3 | 68 | 1X | |
| 4 | 68 | 1X | 6082-1916 |
| 5 | 230 | 1X | |

Replace the Table 2 beginning at page 24 with the following rewritten Table 2:

Table 2. Description of GRP and HRG viruses

| ENV # | Position of Ligand Insertion (A.A. Location) | | Deletion of Nucleotides in Envelope |
|--------|--|-----------|--|
| <hr/> | | | |
| GRP | CAAA – EQRLGNQWAVGHLM – TRC (SEQ ID NO:18) | | |
| <hr/> | | | |
| GRP-1 | 1 | | |
| GRP-2 | 38 | | |
| GRP-3 | 38 | 5990-6082 | |
| GRP-4 | 68 | | |
| GRP-5 | 68 | 6082-1916 | |
| GRP-6 | 120 | | |
| GRP-7 | 120 | 6238-6281 | |
| GRP-8 | 185 | | |
| GRP-9 | 230 | | |
| GRP-10 | 235 | | |
| GRP-11 | 310 | | |
| GRP-12 | 321 | | |
| GRP-13 | 382 | | |
| GRP-14 | 388 | | |

Del. 3 A.A.

FM D PSRY L

M

HRG CAAA - SHLVKCAEKEKTFVNGGECYRVKTYGYLMCKCPNEFTGDRCQNYVIAS - TRC
 (SEQ ID NO:26)

Applicant : Michael R. Green et al.
Serial No. : Not yet assigned
Filed : Herewith
Page : 5 of 6

Attorney's Docket No.: 07917-166US1 / UMMC 02-28

| | | |
|-------|-----|-----------|
| HRG-1 | 1 | |
| HRG-2 | 38 | |
| HRG-3 | 38 | 5990-6082 |
| HRG-4 | 68 | |
| HRG-5 | 68 | 6082-1916 |
| HRG-6 | 120 | |
| HRG-7 | 185 | |
| HRG-8 | 230 | |
| HRG-9 | 235 | |
